(Q30776024)

26 June 2017

1 reference

title

Subclinical and asymptomatic parathyroid disease: implications of emerging data (English)

1 reference

26 June 2017

David P Macfarlane

1

1 reference

26 June 2017

Ning Yu

series ordinal

2

1 reference

26 June 2017

Graham P Leese

series ordinal

3

1 reference

26 June 2017

publication date

24 October 2013

1 reference

The Lancet: Diabetes & Endocrinology

26 June 2017

published in

1 reference

26 June 2017

volume

1

1 reference

26 June 2017

issue

4

1 reference

26 June 2017

page(s)

329-340

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

26 June 2017

1 reference

7 January 2021

Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Clinical practice. Primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Genetic defects associated with familial and sporadic hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Altered parathyroid set point to calcium in familial hypocalciuric hypercalcaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Vitamin D assays: past and present debates, difficulties, and developments

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Serum Calcium Survey for Hyperparathyroidism: Results in 50,000 Clinic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Blood pressure in subjects with hypercalcaemia and primary hyperparathyroidism detected in a health screening programme

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Incidence and prevalence of primary hyperparathyroidism in a racially mixed population

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Survival after the diagnosis of hyperparathyroidism: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Premature death in patients operated on for primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Thirteenth annual meeting of the American Society for Bone and Mineral Research. San Diego, California, August 24-28, 1991. Program and abstracts

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Age as a criterion for surgery in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Nephrolithiasis and renal calcifications in primary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Effect of renal function on skeletal health in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Surgery for primary hyperparathyroidism: are the consensus guidelines being followed?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Renal stones and calcifications in patients with primary hyperparathyroidism: associations with biochemical variables.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Effect of bone mineral density and parathyroidectomy on fracture risk in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Increased risk of death from primary hyperparathyroidism--an update

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Survival after surgical treatment for primary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Cardiovascular events before and after surgery for primary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Prevalence of primary hyperparathyroidism in patients with diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Arterial stiffness in mild primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Carotid artery plaque thickness is associated with increased serum calcium levels: the Northern Manhattan study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Arterial Hypertension, Metabolic Syndrome and Subclinical Cardiovascular Organ Damage in Patients with Asymptomatic Primary Hyperparathyroidism before and after Parathyroidectomy: Preliminary Results

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Effect of surgery on cardiac structure and function in mild primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

The influence of surgery on the risk of death in patients with primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Nonsurgical management of mild primary hyperparathyroidism - a reasonable option

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

What predicts adverse outcomes in untreated primary hyperparathyroidism? The Parathyroid Epidemiology and Audit Research Study (PEARS)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Carotid vascular abnormalities in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Plasma parathyroid hormone and the risk of cardiovascular mortality in the community

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Vitamin D and primary hyperparathyroidism (PHPT).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

1 reference

7 January 2021

Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Nocturnal calcium, phosphorus and parathyroid hormone in the diagnosis of concealed and subclinical hypoparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

Asymptomatic primary hyperparathyroidism - we have half the answers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970083-4

7 January 2021

10.1016/S2213-8587(13)70083-4

Identifiers

DOI

1 reference

26 June 2017

1 reference